Peer-reviewed veterinary case report
Dogs with parvovirus neutropenia treated with canine G-CSF recover
By Duffy, A et al.·Published in Journal of veterinary pharmacology and therapeutics·2010·Department of Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Hematologic improvement in dogs with parvovirus infection treated with recombinant canine granulocyte-colony stimulating factor.
- Species:
- dog
Plain-English summary
A group of dogs with parvovirus infection and low white blood cell counts were treated with a special medication called recombinant canine granulocyte-colony stimulating factor (rcG-CSF). This treatment helped increase their white blood cell and neutrophil counts more quickly than in dogs that did not receive it, which also meant they spent less time in the hospital. However, it was noted that the survival times for dogs treated with rcG-CSF were shorter compared to those who weren't treated. More research is needed to understand the safety of this treatment fully.
People also search for: dog parvovirus treatment · canine granulocyte-colony stimulating factor · parvo infection recovery time
Abstract
Previously, dogs with canine parvovirus-induced neutropenia have not responded to treatment with recombinant human granulocyte-colony stimulating factor (rhG-CSF). However, recombinant canine G-CSF (rcG-CSF) has not been previously evaluated for treatment of parvovirus-induced neutropenia in dogs. We assessed the effectiveness of rcG-CSF in dogs with parvovirus-induced neutropenia with a prospective, open-label, nonrandomized clinical trial. Endpoints of our study were time to recovery of WBC and neutrophil counts, and duration of hospitalization. 28 dogs with parvovirus and neutropenia were treated with rcG-CSF and outcomes were compared to those of 34 dogs with parvovirus and neutropenia not treated with rcG-CSF. We found that mean WBC and neutrophil counts were significantly higher (P < 0.05) in the 28 dogs treated with rcG-CSF compared to disease-matched dogs not treated with rcG-CSF. In addition, the mean duration of hospitalization was reduced (P = 0.01) in rcG-CSF treated dogs compared to untreated dogs. However, survival times were decreased in dogs treated with rcG-CSF compared to untreated dogs. These results suggest that treatment with rcG-CSF was effective in stimulating neutrophil recovery and shortening the duration of hospitalization in dogs with parvovirus infection, but indicate the need for additional studies to evaluate overall safety of the treatment.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/20646196/